Consensus Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Real-time Estimate Cboe BZX Other stock markets 01:34:10 2024-04-25 pm EDT			5-day change	1st Jan Change
196.9 ^USD	-3.80%		-11.46%	-14.95%

Apr. 22	BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective	MT
Apr. 22	BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target	MT

Evolution of the average Target Price on Madrigal Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

bca9af2c9d8b.i1fswuv2tzgd2hHLtqUcSRA1x4sGgqdlbc3JhK6VQms.yTKHtoec0U1vqk6G1-duJz1Hv71ktegvLJ2nzvGjKQOmZKKng8PEQFW1SA~7a521ef17f9d12824e67c8ab5a7de895

Analyst Recommendations on Madrigal Pharmaceuticals, Inc.

BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective	Apr. 22	MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target	Apr. 22	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing	Apr. 11	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing	Apr. 11	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing	Apr. 04	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing	Apr. 04	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing	Apr. 04	MT
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating	Mar. 20	MT
Madrigal commences $500 million public offering of common stock	Mar. 18	RE
TD Cowen Adjusts Madrigal Pharmaceuticals' Price Target to $390 From $349, Maintains Outperform Rating	Mar. 15	MT
Citigroup Adjusts Madrigal Pharmaceuticals' Price Target to $389 From $382, Maintains Buy Rating	Mar. 15	MT
JMP Securities Adjusts Price Target on Madrigal Pharmaceuticals to $397 From $351, Maintains Market Outperform Rating	Mar. 15	MT
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $375 From $320, Maintains Outperform Rating	Mar. 15	MT
H.C. Wainwright Adjusts Price Target on Madrigal Pharmaceuticals to $425 From $405, Maintains Buy Rating	Mar. 15	MT
B. Riley Upgrades Madrigal Pharmaceuticals to Neutral From Sell After FDA Approval of Rezdiffra, Raises PT to $270 From $155	Mar. 15	MT
HC Wainwright Adjusts Madrigal Pharmaceuticals' Price Target to $405 From $275, Maintains Buy Rating	Mar. 12	MT
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $320 From $300, Maintains Outperform Rating	Mar. 01	MT
B. Riley Downgrades Madrigal Pharmaceuticals to Sell From Neutral, Says Nearly All Stock Scenarios Point to Higher Likelihood of Downside; Adjusts PT to $155 From $204	Feb. 27	MT
B. Riley Downgrades Madrigal Pharmaceuticals to Sell From Neutral, Cuts Price Target to $155 From $204	Feb. 26	MT
Piper Sandler Adjusts Price Target on Madrigal Pharmaceuticals to $336 From $305, Maintains Overweight Rating	Jan. 24	MT
Jefferies Cuts Madrigal Pharmaceuticals Price Target to $321 From $340, Maintains Buy Rating	Jan. 18	MT
B. Riley Raises Madrigal Pharmaceuticals' PT to $204 From $154 on Increased Resmetirom Pricing Guidance, Keeps Neutral Rating	Jan. 17	MT
HC Wainwright Adjusts Madrigal Pharmaceuticals' Price Target to $275 From $225, Maintains Buy Rating	Nov. 13	MT
B. Riley Slashes Price Target on Madrigal Pharmaceuticals to $154 From $224, Neutral Rating Kept	23-10-11	MT
Fed rates at 7%: Is it on the cards?	23-09-26

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

204.6 USD

Average target price

377.1 USD

Spread / Average Target

+84.25%

High Price Target

565 USD

Spread / Highest target

+176.08%

Low Price Target

150 USD

Spread / Lowest Target

-26.70%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Madrigal Pharmaceuticals, Inc.

BofA Securities
Evercore ISI
TD Cowen
Citigroup
JMP Securities
B. Riley
HC Wainwright
Oppenheimer
Piper Sandler
Jefferies & Co.
Canaccord Genuity
UBS
SVB Securities LLC
Goldman Sachs
BMO Capital
Chardan

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar